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Introduction: Different transfusion ratio concepts of packed red blood cells (pRBCs), fresh frozen plasma (FFP) and
platelets (PLTs) have been implemented in trauma care, but the optimal ratios are still discussed. In this study the
hemostatic potential of two predefined ratios was assessed by using an in vitro thrombelastometric approach.
Furthermore, age effects of reconstituted blood were analyzed.
Methods: Whole blood (WB) of voluntary donors was separated into pRBCs, FFP and PLTs and reconstituted into
the ratios 1:1:1 and 3:1:1 at day 1, 4, 14, and 24. Standard blood count, electrolytes and coagulation proteins
were quantified. The functional coagulation in ratio- and age-specific groups was evaluated using rotational
thromboelastometry (ROTEM).
Results: Several coagulation factors reduced significantly in the 3:1:1 ratio and were consistent with increased
INR, decelerated clot formation times and A10 (amplitude 10 minutes after clotting time (CT)), flattened α-angle
during the EXTEM and diminished MCF for distinct time points during the INTEM, FIBTEM and APTEM assays.
With rising age of pRBCs the pH, sodium and potassium reached non-physiological levels.
Conclusion: Under standardized in vitro conditions the higher amount of pRBCs in the 3:1:1 ratio diluted
coagulation factors significantly on the expense of its functional coagulation capacity as revealed by ROTEM
results. Thus, the coagulation functionality of the 1:1:1 ratio predominated.
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componentsIntroduction
As there is less doubt about the components to be ad-
ministered during transfusion the evidence for an appro-
priate transfusion ratio is still lacking [1]. Different
ratios of pRBCs, FFP and PLTs are applied in clinical
practice [2-4] at which the 1:1:1 ratio has been adopted
by trauma centers worldwide for the acute treatment of
bleeding trauma patients [5,6]. For massive transfusion
the use of a RBC:FFP ratio of 1:1 or 2:1 was recom-
mended based on systematic reviews [7-11] and a reduc-
tion of death risk for trauma patients was associated* Correspondence: marc.maegele@t-online.de
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unless otherwise stated.when transfused in the range of 1:1 to 2.5:1. Currently,
the PROPPR study as a phase III prospective random-
ized trial was conducted by several trauma centers in the
United States that targets the efficacy of the transfusion
ratio 1:1:1 compared to 2:1:1 (pRBCs:FFP:PLTs) within a
massive transfusion (MT). Overall limited evidence due
to retrospective or unfinished prospective designs [12]
and numerous potential confounders [1,10,13-16] as well
as poor compliance to MT protocols (MTP) during re-
suscitation limits the expressiveness and results of these
studies.
Besides transfusion ratios the application of blood
products stored less than two weeks (fresh blood) or
more than 14 days (old blood) is also crucially discussed.
Previously, lower postoperative complications and in-
creased long-term survival were observed after cardiac
surgery when transfusing fresh compared to older bloodl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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sion related acute lung injury (TRALI) was shown after
administering stored pRBC in different animal studies
[18,19] with comparable results in additional studies
[20-24]. Furthermore the erythrocyte cell membrane
deformability irreversibly decreased with storage dur-
ation and might be responsible for reduced oxygen
transport [24-29].
The present study addressed the question of a pre-
dominance of the ratios 1:1:1 and 3:1:1 of pRBCs, FFP
and PLTs in contrast to whole blood on the one hand
and age-specificities of fresh and old blood on the other.
For this purpose, they were compared in vitro under
standardized conditions by measuring electrolytes, blood
and coagulation proteins as well as analyzing functional-
ity of coagulation and at distinct time points.
Methods
Blood donation and further processing
After institutional review board approval and written in-
formed consent a volume of 450 ml type A blood of six
voluntary donors was collected in standard bags supple-
mented with 63 ml of CPD (citrate, phosphate, dextrose)
stabilization solution. Initially, the blood was stored for
20 hours at validated CompoCool plates (Fresenius Kabi,
Bad Homburg, Germany) prior to leukocyte-depletion
(by filtering) and separation (by centrifugation) into
pRBCs, FFP and PLTs. The pRBC of 260 ± 50 ml volume
contained 100 ml of SAG-M (adenine, glucose and man-
nitol) solution and were stored at 4°C ± 2°C until usage.
FFP was portioned in 250 ± 30 ml bags, shock-frozen
and stored at −30°C. Due to the short storage life a
maximum four days old PLTs bag of 260 ± 40 ml was
used that had been incubated under constant agitation
at 22°C ± 2°C.
Since the volume of the blood product bags differed,
the pRBCs, FFPs and PLTs were weighted first before
calculating its percentage of volume prior reconstitution
which allowed a realistic transfusion procedure of theFigure 1 Procedure of blood separation and reconstitution as well asratios 1:1:1 and 3:1:1 to a final volume of 50 ml. All mea-
surements were performed at day one, four, 14, and 24.
Additionally, whole blood was measured at day one. The
detailed proceeding was represented in Figure 1.
Measurement of blood parameters
All measurements were performed at the Institute of
Transfusion Medicine, Cologne-Merheim Medical Centre.
The standard hemogram (Full Blood Count, FBC) pa-
rameters erythrocytes, leucocytes, platelets, hemoglobin,
hematocrit, mean corpuscular volume (MCV), mean
corpuscular hemoglobin (MCH), mean corpuscular
hemoglobin concentration (MCHC), and red blood cell
distribution width (RDW) were measured on the Cell-
Dyn 1700 Hematology Analyzer (Abbott Laboratories,
Abbott Park, USA). International normalized ratio (INR),
partial thromboplastin time (PTT), fibrinogen, antithrom-
bin, the factors II, V, VII, VIII, IX, X, XI, XII, and VIII, pro-
tein C, protein S, d-dimer, vonWillebrand factor activity
(vWF:a), and vonWillebrand factor Antigen (vWF:Ag)
were quantified following the manufacturer’s manuals (In-
strumentation Laboratory Company; Bedford, USA; Sie-
mens Healthcare Diagnostics Products GmbH, Marburg,
Germany) by using the ACLTOP system (Instrumentation
Laboratory Company; Bedford, USA) and the APACT 4S
Plus (Rolf Greiner BioChemica, Flacht, Germany).
The values of sodium, potassium, calcium, and the pH
were determined by blood gas analysis via the IRMA
TruPoint Blood Analysis System (Keller Medical GmbH,
Bad Soden, Germany).
ROTEM® analysis
Kinetics of hemostasis was followed by ROTEM delta
analysis in accordance to the manufacturer’s instructions
(Tem International GmbH, Munich, Germany) (Figure 2).
The 30 minutes thromboelastometric measurement in-
cluded the extrinsically activated assay with tissue factor
(EXTEM), the intrinsically activated test using ellagic acid
(INTEM), the extrinsically activated test with tissue factorsubsequent experiments.
Figure 2 Kinetics of hemostasis as demonstrated by a viscoelastic test (ROTEM, Tem Innovations GmbH).
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as the extrinsically activated assay after blocking hyperfi-
brinolysis by aprotinin (APTEM). The parameters clotting
time (CT), clot formation time (CFT), α-angle, amplitude
10 minutes after CT (A10), and maximal clot firmness
(MCF) were analyzed for the EXTEM, INTEM and APTEM
assays while the CFT was not determined for FIBTEM.
Statistics
Collected data were analyzed by the nonparametric
Kruskal-Wallis test to assess the effects of time and ratio
in the different time-by-ratio groups using the IBM SPSS
Statistics, version 21.0 (Armonk, NY, USA). P values
were corrected in the subsequent pairwise comparison
of groups. Differences were considered statistically sig-
nificant at p < 0.05.
The cumulative comparison of coagulation factor activ-
ity was performed by calculating the overall mean of all
factors for the WB, 1:1:1 and 3:1:1 group, respectively.
Results
Blood count and electrolytes
Irrespective of blood product age, several measured pa-
rameters differed between the ratios 1:1:1 and 3:1:1
(Table 1). The quantity of erythrocytes was significantly
lower in the 1:1:1 group compared to WB. Platelets were
elevated in the 1:1:1 ratio at all points in time and dif-
fered significantly from the corresponding levels of the
whole blood. Leucocyte depletion of the original blood
samples resulted in a drastically decline in both ratios
(<500/μl). While hemoglobin and hematocrit levels of the
3:1:1 ratio and the WB were likewise, the 1:1:1 ratio had
significantly reduced levels in comparison with both groups
at the reviewed time points. Overall, age-specific differences
were not observed for erythrocytes, platelets, hemoglobin,
and hematocrit. Similarly, MCV, MCH and RDW remained
constant and were not affected by age or ratio.
Only few age effects could be observed (Table 2) and
thereof most notably the values of potassium andsodium. Independent of ratio potassium increased pro-
gressively over time being 2.4- and 4.6-fold higher after
24 days in the 1:1:1 and 3:1:1 ratio, respectively. In con-
trast, sodium reduced with increasing age and differed
significantly in both ratios between day one and 24. The
environment of the reconstituted blood slightly acidified
as in both ratios the pH value decreased with age and
was reduced stronger in the 3:1:1 group from day four
(Table 2). No alteration of calcium was determined dur-
ing the measurement.
Coagulation proteins
For almost all coagulation factors ratio-specific reduc-
tions in the 3:1:1 group were observed at any time point
when comparing both ratios (Table 1). The factors VII,
IX, X and XII were constantly and significantly reduced
in 3:1:1 samples, independent of age while the factors II,
V, and XIII significantly declined not before day four.
Similar to the blood count parameter the quantity of co-
agulation factors was affected minor by age (Table 2).
Although several factors tended to be reduced after 24 days
only the factors II, V and VII measured in the 1:1:1 ratio
and factors IX, XI and XIII in the 3:1:1 group reached the
level of significance. The cumulative factors were compar-
able in the WB and 1:1:1 group whereas a precise decline
was observed when comparing both groups to the 3:1:1
ratio at day 1 or when comparing the 1:1:1 with the 3:1:1
ratio at the respective time points (Figure 3).
The activity of the coagulation inhibitors antithrombin
and protein C as well as its cofactor protein S were sig-
nificantly lowered in the 3:1:1 compared to WB (day
one) and in most cases considerably reduced in 1:1:1 ra-
tio at all ages (Table 2). Fibrinogen was also diluted in
3:1:1 samples from day four on (Table 1).
Functionality of coagulation
Consistent with the reduction of coagulation proteins in
the 3:1:1 ratio an elevated PTT and INR were observed
in the 1:1:1 group irrespective of age. Both values
Table 1 Significant ratio-specific differences of the ratios 1:1:1 and 3:1:1
Parameter Day 1 Day 4 Day 14 Day 24
WB 1:1:1 3:1:1 1:1:1 3:1:1 1:1:1 1:1 1:1:1 3:1:1
Erythrocytes [×106/μl] 3.79 ± 0.29 2.14 ± 0.54+ 3.65 ± 0.85 2.01 ± 0.14* 3.68 ± 0.29 1.96 ± 0.13* ± 0.34 2.09 ± 0.64* 3.08 ± 0.61
Leukocytes [×103/μl] 6.55 ± 2.05 0.25 ± 0.05+ 0.33 ± 0.1+ 0.37 ± 0.08 0.33 ± 0.14 0.35 ± 0.1 5 ± 0.08 0.45 ± 0.1 0.5 ± 0.18
Platelets [×103/μl] 236.5 ± 43.1 348.5 ± 36.39+,* 226.5 ± 28.51 327.5 ± 22.42* 181 ± 44.09 359.17 ± 20.68* 1.5 ± 38.83 334.83 ± 37.5* 231.5 ± 58.11
Hemoglobin [g/dl] 11.78 ± 1.11 6.6 ± 1.67+,* 11.43 ± 2.54 6.2 ± 0.56* 11.42 ± 1.08 6.12 ± 0.5* .38 ± 1.25 6.47 ± 2.27* 9.76 ± 1.71
Hematocrit [%] 37.08 ± 3.21 20.85 ± 4.29+,* 35.7 ± 7.14 20.27 ± 1.55* 37.13 ± 3.19 19.5 ± 1.76* .97 ± 3.88 21.33 ± 7.26 30.92 ± 5.29
MCHC [g/dl] 31.75 ± 0.7 31.47 ± 1.27 31.9 ± 0.65 30.57 ± 0.6 30.72 ± 0.5 30.75 ± 0.18* .5 ± 0.64 30.25 ± 0.49 30.83 ± 0.7
pH 6.92 ± 0.06 7.04 ± 0.04+ 6.95 ± 0.05 7.03 ± 0.05* 6.9 ± 0.04 6.91 ± 0.08* 6 ± 0.03 6.89 ± 0.03* 6.69 ± 0.06
Sodium [mM] 139.67 ± 2.33 142.62 ± 6.15 145.37 ± 5.14 140.48 ± 1.63* 142.3 ± 0.89 138.67 ± 0.81 8.43 ± 2.09 137.42 ± 0.99 136.72 ± 1.67
Potassium [mM] 3.33 ± 0.4 3.12 ± 0.38 2.83 ± 0.78 3.91 ± 0.38* 4.69 ± 0.35 6.72 ± 1.3* 9 ± 0.95 7.45 ± 0.48* 13.01 ± 0.15
EXTEM CFT [s] 101.83 ± 49.17 59.83 ± 10.94* 125.33 ± 27.5 54.83 ± 5.49* 127.67 ± 50.71 59.33 ± 16.46* 9.5 ± 46.87 74.33 ± 27.98 99.5 ± 34.81
INTEM CFT [s] 133.5 ± 67.16 70.33 ± 24.83 144.17 ± 99.03 55.5 ± 6.8* 119.5 ± 39.51 114.17 ± 94.2 6.5 ± 78.58 67 ± 34.48 92.5 ± 18.17
APTEM CFT [s] 119.17 ± 74.34 72.67 ± 22.81 108 ± 33.89 70.5 ± 16.88* 131.33 ± 57.6 66.83 ± 19.06* 3.5 ± 44.28 65.33 ± 30.74 84.33 ± 19.31
INR 1.12 ± 0.1 1.03 ± 0.05* 1.23 ± 0.08 1.13 ± 0.05* 1.52 ± 0.25 1.12 ± 0.04* 3 ± 0.15 1.17 ± 0.08* 1.45 ± 0.14
PTT [s] 38.33 ± 4.59 33.67 ± 3.83 36.83 ± 5.49 33.83 ± 2.79* 44.83 ± 6.88 38.5 ± 4.14* .67 ± 7.15 36.83 ± 4.4* 43.5 ± 5.32
Fibrinogen [mg/dl] 254.17 ± 51.33 226.83 ± 23.79 173.8 ± 31.3+ 224.33 ± 21.94* 147.33 ± 30.74 215.17 ± 25.56* 3.67 ± 16.46 240.17 ± 20.47* 170 ± 17.12
Antithrombin [%] 77.17 ± 7.41 68.83 ± 7.78 49.17 ± 8.54+ 64.67 ± 3.98* 38.17 ± 7.25 67.17 ± 3.31* .33 ± 6.12 63.17 ± 3.43* 41.33 ± 3.27
Factor II [%] 82.33 ± 8.33 76.33 ± 4.23 55.17 ± 7.19+ 74 ± 5.48* 46.33 ± 8.71 68.5 ± 8.07* .83 ± 9.7 63.17 ± 5.34 45.67 ± 5.54
Factor V [%] 81.17 ± 7.41 72.67 ± 6.89 53 ± 10.1+ 57.33 ± 4.41* 34.5 ± 6.25 58.67 ± 3.72* .83 ± 2.64 56.33 ± 6.98* 40.33 ± 5.09
Factor VII [%] 73.67 ± 11.33 79.83 ± 10.46* 56.33 ± 7.76 67.17 ± 9.15* 42 ± 9.27 64.67 ± 9.67* .33 ± 8.31 61.17 ± 11.41* 45 ± 9.92
Factor VIII [%] 95.33 ± 29.12 83.75 ± 13.35 57.83 ± 10.8+ 71.8 ± 9.88* 46.17 ± 16.55 53.83 ± 11.2* .17 ± 8.8 71.67 ± 30.94 53.33 ± 23.89
Factor IX [%] 89 ± 8.2 95 ± 5.22* 70.67 ± 8.62 87 ± 5.33* 54.5 ± 10.56 74.5 ± 10.91* .17 ± 11.36 77.33 ± 16.37* 50.67 ± 9.14
Factor X [%] 73.5 ± 9.09 79.33 ± 5.92* 54.17 ± 5.88 72.33 ± 8.24* 48.83 ± 6.68 68.67 ± 13.98* .17 ± 11.07 71.17 ± 10.82* 49.83 ± 10.38
Factor XI [%] 83.8 ± 29.8 96 ± 15.3* 71.67 ± 6.35 91.83 ± 18.8 72.83 ± 33.88 72.67 ± 15.07* .5 ± 12.32 66.5 ± 11.78* 48.17 ± 8.33
Factor XII activity [%] 86.17 ± 28.27 75.67 ± 9.14* 54.67 ± 8.26+ 88 ± 10.1* 48.33 ± 13.85 76.5 ± 22.73* .17 ± 20.44 69.67 ± 16.01* 48.33 ± 9.42
Factor XIII [%] 115.67 ± 11.18 100.67 ± 12.4 77.17 ± 10.67+ 97.5 ± 11.71* 67.17 ± 16.04 86.33 ± 6.38* .5 ± 4.09 92.17 ± 19.05* 61 ± 1.79
Protein C activity [%] 71.67 ± 13.98 70.33 ± 5.96* 50.5 ± 4.97+ 70.67 ± 7.42* 41.33 ± 8.36 60.67 ± 6.74* .33 ± 7.26 63.67 ± 5.16* 48.17 ± 6.97
Protein S activity [%] 89.17 ± 16.93 60.33 ± 7.12 43.17 ± 11.41+ 33 ± 4.34* 21.17 ± 8.82 55 ± 8.12* .33 ± 7.39 43.8 ± 15.42 28.83 ± 12.24
v. Willebr. activation [%] 128.83 ± 39.78 97 ± 19.01 72.2 ± 15.9+ 98.67 ± 18.35* 67.17 ± 23.04 67.5 ± 26.61 ± 14.56 82.33 ± 28.11 60.17 ± 22.11
v. Willebr. antigen [%] 141.83 ± 45.28 112.67 ± 27.81 77.2 ± 17.08+ 114.83 ± 27.69* 71.67 ± 22.17 78 ± 25.87 .17 ± 17.68 107.83 ± 39.91 76.5 ± 28.74
















































Table 2 Significant age-specific differences at day one, four, 14, and 24
Parameter 1:1:1 3:1:1
Day 1 Day 4 Day 14 Day 24 Day 1 Day 4 Day 14 Day 24
Leukocytes
[×103/μl]
0.25 ± 0.05c 0.37 ± 0.08 0.35 ± 0.1 0.45 ± 0.1 0.33 ± 0.1 0.33 ± 0.14 0.25 ± 0.08 0.5 ± 0.18
pH 7.04 ± 0.04b,c 7.03 ± 0.05e 6.91 ± 0.08 6.89 ± 0.03 6.95 ± 0.05b,c 6.9 ± 0.04e 6.76 ± 0.03 6.69 ± 0.06
Sodium [mM] 142.62 ± 6.15c 140.48 ± 1.63e 138.67 ± 0.81 137.42 ± 0.99 145.37 ± 5.14b,c 142.3 ± 0.89e 138.43 ± 2.09 136.72 ± 1.67
Potassium [mM] 3.12 ± 0.38b,c 3.91 ± 0.38e 6.72 ± 1.3 7.45 ± 0.48 2.83 ± 0.78b,c 4.69 ± 0.35e 9.19 ± 0.95 13.01 ± 0.15
INTEM CT [s] 204.83 ± 13.6c 229.33 ± 28.51 243.5 ± 121.51 284.33 ± 67.57 206.83 ± 16.46 200.83 ± 14.93e 245 ± 84.52 259.83 ± 25.86
FIBTEM CT [s] 57.83 ± 10.65 108.33 ± 91.24 69.5 ± 38.9 46.17 ± 29.17 84.33 ± 15.72c 52.33 ± 26.24 132.33 ± 107.69 45.17 ± 19.09
INR 1.03 ± 0.05c 1.13 ± 0.05 1.12 ± 0.04 1.17 ± 0.08 1.23 ± 0.08 b 1.52 ± 0.25 1.53 ± 0.15 1.45 ± 0.14
Factor II [%] 76.33 ± 4.23c 74 ± 5.48 68.5 ± 8.07 63.17 ± 5.34 55.17 ± 7.19 46.33 ± 8.71 43.83 ± 9.7 45.67 ± 5.54
Factor V [%] 72.67 ± 6.89a,c 57.33 ± 4.41 58.67 ± 3.72 56.33 ± 6.98 53 ± 10.1a,b 34.5 ± 6.25 35.83 ± 2.64 40.33 ± 5.09
Factor VII [%] 79.83 ± 10.46c 67.17 ± 9.15 64.67 ± 9.67 61.17 ± 11.41 56.33 ± 7.76 42 ± 9.27 41.33 ± 8.31 45 ± 9.92
Factor IX [%] 95 ± 5.22b 87 ± 5.33 74.5 ± 10.91 77.3 ± 16.37 70.67 ± 8.62c 54.5 ± 10.56 51.17 ± 11.36 50.67 ± 9.14
Factor XI [%] 96 ± 15.3 91.83 ± 18.8 72.67 ± 15.07 66.5 ± 11.78 71.67 ± 6.35b,c 72.83 ± 33.88 49.5 ± 12.32 48.17 ± 8.33
Factor XIII [%] 100.67 ± 12.4 97.5 ± 11.71 86.33 ± 6.38 92.17 ± 19.05 77.17 ± 10.67c 67.17 ± 16.04 65.5 ± 4.09 61 ± 1.79
Protein C
activity [%]
70.33 ± 5.96 70.67 ± 7.42 60.67 ± 6.74 63.67 ± 5.16 50.5 ± 4.97b 41.33 ± 8.36 37.33 ± 7.26 48.17 ± 6.97
Protein S
activity [%]
60.33 ± 7.12b 33 ± 4.34 55 ± 8.12 43.83 ± 15.42 43.17 ± 11.41a 21.17 ± 8.82 33.33 ± 7.39 28.83 ± 12.24
D-dimer [μg/l] 216.6 ± 48.43b 239.5 ± 43.98d 123 ± 26.78 156 ± 50.45 185.2 ± 36.64 180.67 ± 37.6 119.5 ± 17.04 150.5 ± 32.44
Values are represented as mean ± standard deviation. Lowercases indicate significant differences (p < 0.05) between: a - day 1 and 4, b - day 1 and 14, c - day 1
and 24, d - day 4 and 14, e - day 4 and 24, and f - day 14 and 24, respectively.
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day one (Table 1). Furthermore, the INR trended to in-
crease with age in both ratios. A declined functionality
of the extrinsic and intrinsic system was also measured
by ROTEM analysis. The CFT significantly decelerated
at almost all time points in the 3:1:1 group of the
EXTEM approach (Table 1). Similarly, CTs were pro-
longed by trend in the 3:1:1 group, however, not reach-
ing significant level. Also the α-angle and the clot
amplitudes after 10 and 30 minutes declined in the 3:1:1
ratio at day one, four and 14 (Figure 4).
For the INTEM, FIBTEM and APTEM assays the
main difference were observed after four and 14 days
(Table 1, Figure 4). Thereafter mostly tendencies were
determined due to a high variation within the groups.
However, the MCF seemed to be the most consistent
value in these three approaches providing significant de-
clines in the 3:1:1 ratio irrespective of the activation
pathway. As observed for other measured values the age
differences were inconsistent and being present for few
comparisons of EXTEM α-angle as well as for INTEM
and FIBTEM CTs (Table 2).
Discussion
The ratio concept
Over 10 years ago the correlation of transfusion practices
and patients’ outcome was stronger focused in traumaresearch. Several publications [2,10,11,30] underlined the
superiority for using defined ratios of pRBCs and FFPs
solely or combined with PLTs. Due to heterogeneity such
as patients’ inclusion criteria (if they were even defined)
and in the applied ratios (1:1; 2:1, 3:1 etc.) the evidence of
these studies was limited. In 2007, Borgman et al. [2]
firstly presented a systematic analysis of trauma care in-
cluding a transfusion ratio concept that increased the sur-
vival rate in major bleeding patients. This study still
represents the unproven guideline in handling these kinds
of seriously injured patients. Currently, the multicenter
PROPPR study systematically compared the transfusion
ratios 1:1:1 and 2:1:1 (pRBCs:FFP:PLTs) in a clinical trial
and brought first (but final) evidence in the discussion re-
garding transfusion ratios [31].
In this in vitro study the physiological characteristics
of the 3:1:1 ratio go along with a reduction of all coagu-
lation factors resulting in a lowered hemostasiological
potential that was indicated by elevated INR and visco-
elastic tests. The thrombelastometric findings (ROTEM)
in dilution effects in the 3:1:1 ratio became evident by a
decreased dynamic clot formation and clot quality as in-
dicated by a flattened α-angle and a lowered clot firm-
ness after 10 and 30 minutes (A10, MCF). Furthermore,
a trend of decelerated clot formation could be observed.
There was no evidence that the processing of plasma
(freezing, storage, thawing) may explain the changes in
Figure 3 Quantitative cumulative factor quantity (summing up coagulation factors FII, FV, FVII, FVIII, F IX, FX, FXI, FXII, FXIII) and INR of
the WB, 1:1:1 and 3:1:1 groups. Levels are represented as mean and standard deviation. Bars are depicted as dotted (WB), light grey (1:1:1) and
dark grey (3:1:1). Significances were observed at *p < 0.05; **p < 0.01; ***p < 0.001.
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group, since 10 days of storage and subsequent thawing
did not affect coagulation factors as shown previously
[32]. In addition, this proceeding effect would have been
observed in the 1:1:1 ratio as well. To ensure the allocation
of functional factors in FFPs and to further minimize in-
fluencing effects on coagulation, maximum 4 days old
factor-rich plasma was used at any time point before re-
constitution. Thus, the lower quantity of coagulation fac-
tors whether significantly reduced in the 3:1:1 ratio or
trend to be decreased can rather be explained by diluting
effects than by inactivation of factors. Furthermore, cumu-
lative factors were comparable between WB and 1:1:1 pro-
viding an adequate initial basis for coagulation [30,33]. In
summary the hemostasiological potential of the 1:1:1 ratio
rather referred to that of WB. Transfusion ratios leading
to a nearly physiological hemostasiological potential andan effective coagulation may reduce the amount of pRBCs
being transfused. According to the current European
guideline [34] transfusion of pRBC is recommended in pa-
tients with Hb values below 7 mg/dl.
The findings of the present study were in line with re-
sults of a recently published in vitro study in which a di-
lution effect in a 3:1 (pRBC:FFP) ratio was determined
by simulating postpartum hemodilutional coagulopathy
[35]. Therefore, there seemed to be a superiority of the
1:1 ratio of pRBC and FFP transfusion optimized by an
additional application of the same ratio of PLTs. Interest-
ingly, no dilution effect due to FFP was observed though
not only concentrates of clotting factors were used.
Similar results were reported for a thrombelastography
(TEG) approach in which different ratios of pRBC:FFP:
PTL were analyzed in vitro. In line with the results of
the present study, a higher proportion of pRBCs such as
Figure 4 Functional characterization of coagulation via ROTEM analysis. The α-angle, amplitude after 10 minutes (A10) and maximum clot
firmness (MCF) after 30 minutes of the EXTEM, INTEM, FIBTEM, and APTEM assays are represented as mean and standard deviation. Bars are
depicted as dotted (WB), light grey (1:1:1) and dark grey (3:1:1). Significances were observed at *p < 0.05; **p < 0.01; ***p < 0.001. Age differences
(p < 0.05) were indicated with the lowercases a (day 1↔ 4), b (day 1↔ 14), c (day 1↔ 24), d (day 4↔ 14), e (day 4↔ 24), and f (day 14↔ 24),
respectively.
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form a stable clot (reduced angle and maximal ampli-
tude) [36].
This in vitro experiment enabled the assessment of
quantitative and functional coagulation under stan-
dardized environments and revealed main findings in
dilution and associated effects on functional coagula-
tion. However, interrelated physiological impact on
TIC like hypothermia, acidosis, inflammation, shock
or the preliminary treatments such as pre-hospital vol-
ume administration [37-39] and therefore, dilution
and hyperpermeability, shedding of the endothelial
glycocalyx with autoheparinization [40] and activation
of the protein C pathway [41,42] influence its coagula-
tion potency. Disease pattern leading to major bleeding
are very individual. Therefore, we could only propose a
possible influence of the applied ratio of blood products in
human. Efficient therapy of coagulopathy reduces signifi-
cantly morbidity and mortality in trauma patients [2,43].
Independent from (surgical) therapies, coagulopathy is
recognized as independent disease with an individual need
for therapy nowadays [44,45].Age of blood products
Addressing the question if there are differences in newer
compared to older blood trends of reduced corpuscular
components after 24 days were shown. Inverse the high-
est potassium and lowest pH value were measured at
day 24 which might be explained by an increasing eryth-
rocytes degradation [46]. With regard to clinical practice
one should consider that potassium levels higher than
8 mmol/l have to be taken into further account when
applying the 3:1:1 ratio. As demonstrated in previous
clinical studies [27-29,47,48] in which the length of stor-
age of pRBC influenced hemolysis, changes in deform-
ability as well as osmotic fragility the results of this
study did not reveal any continuous age effect according
to the hemostasiological potential. However, the changes of
potassium (13.01 ± 0.15 mM), sodium (136.72 ± 1.67 mM)
and pH levels (6.69 ± 0.06) associated with aging blood
products cannot be disregarded when applying to patients
after 24 days of storage.
Regarding clotting time and clot formation a continu-
ous but not significant increase was detected for INTEM
while FIBTEM values reacted vice versa.
Driessen et al. Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine  (2015) 23:2 Page 8 of 9Conclusions
This systematic in vitro study offers valuable information
about transfusion ratios as well as influencing age effects
on coagulation. With regard to limitations of in vitro tri-
als, the presented results suggest a superiority of 1:1:1
ratio in a physiological setting in case of transfusion en-
couraging higher use of plasma rather than pRBCs.
Thus, dosage, ratio and administration of blood compo-
nents still remain a dichotomy between benefits and
harms whereby this study highlighted the need for
multi-center clinical trials to determine the optimal
transfusion strategy.
Key messages
 The higher proportion of pRBCs of the 3:1:1 ratio
resulted in dilution properties of almost all
coagulation factors and inhibitors.
 Dilution likewise affected the hemostasiological
potential which was indicated by an elevated PTT
and INR in the 3:1:1 compared to 1:1:1 group.
 The reduced functional coagulation of the 3:1:1 ratio
was further specified by a decelerated CFT, flattened
α-angle and diminished MCF of the ROTEM
analysis.
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